[1] |
Shibuya M. VEGF-VEGFR signals in health and disease[J]. Biomol Ther (Seoul), 2014, 22(1):1-9.
|
[2] |
Mendel DB,Laird AD,Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship [J]. Clin Cancer Res, 2003, 9(1):327-337.
|
[3] |
Abrams TJ,Lee LB,Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer[J]. Mol Cancer Ther, 2003, 2(5):471-478.
|
[4] |
Murray LJ,Abrams TJ,Long KR, et al. SU11248 inhibits tumor growth and CSF-1R- dependent osteolysis in an experimental breast cancer bone metastasis model[J]. Clin Exp Metastasis, 2003, 20(8):757-766.
|
[5] |
Wilhelm S,Carter C,Lynch M, et al. Discoveryand development of sorafenib: a multikinase inhibitor for treating cancer[J]. Nat Rev Drug Discov, 2006, 5(10):835-844.
|
[6] |
Lierman E,Lahortiga I,Van Miegroet H, et al. The ability of sorafenib to inhibit oncogenic PDGFR- beta and FLT3 mutants and overcome resistance to other small molecule inhibitors[J]. Haematologica, 2007, 92(1): 27-34.
|
[7] |
Motzer RJ,Jonasch E,Agarwal N, et al. Kidney cancer, version 2.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017, 15(6):804-834.
|
[8] |
Von Mehren M,Randall RL,Benjamin RS, et al. Gastrointestinal stromal tumors, version 2.2014[J]. J Natl Compr Canc Netw, 2014, 12(6):853-862.
|
[9] |
ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2014, 25 Suppl 3:iii21-26.
|
[10] |
Koo DH,Ryu MH,Kim KM, et al. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor[J]. Cancer Res Treat, 2016, 48(4):1155-1166.
|
[11] |
Kulke MH,Shah MH,Benson AB 3rd, et al. Neuroendocrine tumors, version 1.2015[J]. J Natl Compr Canc Net, 2015, 13(1):78-108.
|
[12] |
Benson AB 3rd,D'Angelica MI,Abbott DE, et al. NCCN guidelines insights: hepatobiliary cancers, version 1.2017 [J]. Natl Compr Canc Netw, 2017, 15(5):563-573.
|
[13] |
秦叔逵,李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志,2015,20(9):841-847.
|
[14] |
Banerjee S,Dowsett M,Ashworth A, et al. Mechanisms of disease: angiogenesis and the management of breast cancer [J]. Nat Clin Pract Oncol, 2007, 4(9):536-550.
|
[15] |
Paulsson J,Sjöblom T,Micke P, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cance [J]. Am J Pathol, 2009, 175(1):334-341.
|
[16] |
Burstein HJ,Elias AD,Rugo HS, et al. Phase Ⅱ study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J]. J Clin Oncol, 2008, 26(11): 1810-1816.
|
[17] |
Yardley DA,Dees EC,Myers SD, et al. Phase Ⅱ open-label study of sunitinib in patients with advanced breast cancer [J]. Breast Cancer Res Treat, 2012, 136(3): 759-767.
|
[18] |
Curigliano G,Pivot X,Cortés J, et al. Randomized phase Ⅱ study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer [J]. Breast, 2013, 22(5):650-656.
|
[19] |
Barrios CH,Liu MC,Lee SC, et al. Phase Ⅲ randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer[J]. Breast Cancer Res Treat, 2010, 121(1):121-131.
|
[20] |
Bianchi G,Loibl S,Zamagni C, et al. Phase Ⅱ multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer [J]. Anticancer Drugs, 2009, 20(7): 616-624.
|
[21] |
Moreno-Aspitia A,Morton RF,Hillman DW, et al. Phase Ⅱ trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 [J]. J Clin Oncol, 2009, 27(1): 11-15.
|
[22] |
Taylor SK,Chia S,Dent S, et al. A phase Ⅱ study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase Ⅱ consortium [J]. Oncologist, 2010, 15(8): 810-818.
|
[23] |
Hu X,Zhang J,Xu B, et al. Multicenter phase Ⅱ study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer[J].Int J Cancer, 2014, 135(8): 1961-1969.
|
[24] |
Hu X,Cao J,Hu W, et al. Multicenter phase Ⅱ study of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14:820.
|
[25] |
Ebos JM,Lee CR,Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis [J]. Cancer Cell, 2009, 15(3):232-239.
|
[26] |
Yao N,Ren K,Jiang C, et al. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo [J]. Tumour Biol, 2015, 36 (11): 8499-8510.
|
[27] |
陈宇潇,倪成铭,张金梦,等. 乳腺癌血管生成拟态的分子机制研究进展[J/CD]. 中华乳腺病杂志(电子版), 2017, 11(2): 97-101.
|
[28] |
Cooke VG,LeBleu VS,Keskin D, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway [J]. Cancer Cell, 2012, 21(1):66-81.
|
[29] |
Welti JC,Powles T,Foo S, et al. Contrasting effects of sunitinib within in vivo models of metastasis[J]. Angiogenesis, 2012, 15(4):623-641.
|
[30] |
Chung AS,Kowanetz M,Wu X, et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors [J]. J Pathol, 2012, 227(4): 404-416.
|
[31] |
Tian S,Quan H,Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J]. Cancer Sci, 2011, 102(7):1374-1380.
|
[32] |
Bergh J,Bondarenko IM,Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase Ⅲ study[J]. J Clin Oncol, 2012, 30(9): 921-929.
|
[33] |
Crown JP,Diéras V,Staroslawska E, et al. Phase Ⅲ trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer[J]. J Clin Oncol, 2013, 31(23): 2870-2878.
|
[34] |
Robert NJ,Saleh MN,Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase Ⅲ,randomized, open-label trial[J]. Clin Breast Cancer, 2011. 11(2): 82-92.
|
[35] |
Baselga J,Segalla JG,Roché H, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer[J]. J Clin Oncol, 2012, 30(13):1484-1491.
|
[36] |
Baselga J,Zamagni C,Gómez P, et al. RESILIENCE: Phase Ⅲ randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer [J]. Clin Breast Cancer, 2017, 17(8):585-594.
|
[37] |
Schwartzberg LS,Tauer KW,Hermann RC, et al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab [J]. Clin Cancer Res, 2013, 19(10):2745-2754.
|
[38] |
Mariani G,Burdaeva L,Roman L, et al. A double-blind, randomized phase lib study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer (MBC): FM-B07-01 trial [J]. Eur J Cancer, 2011, 47(Suppl 2): 10.
|
[39] |
Gradishar WJ,Kaklamani V,Sahoo TP, et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer[J]. Eur J Cancer, 2013, 49(2): 312-322.
|
[40] |
Luu T,Frankel P,Chung C, et al. Phase Ⅰ/Ⅱ trial of vinorelbine and sorafenib in metastatic breast cancer [J]. Clin Breast Cancer, 2014, 14(2): 94-100.
|
[41] |
Yardley DA,Dickson N,Drosick D, et al. Sorafenib plus ixabepilone as first-line treatment of metastatic HER2-negative breast cancer: a sarah cannon research institute phase Ⅰ/Ⅱ trial [J]. Clin Breast Cancer, 2016, 16(3):180-187.
|
[42] |
Rugo HS,Stopeck AT,Joy AA, et al. Randomized, placebo-controlled, double-blind, phase Ⅱ study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer [J]. J Clin Oncol, 2011, 29(18):2459-2465.
|
[43] |
Martin M,Roche H,Pinter T, et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study [J]. Lancet Oncol, 2011, 12(4):369-376.
|
[44] |
Boer K,Láng I,Llombart-Cussac A, et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase Ⅱ study[J]. Invest New Drugs, 2012, 30(2): 681-687.
|
[45] |
Mayer EL,Scheulen ME,Beckman J, et al. A phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer[J]. Breast Cancer Res Treat, 2013, 140(2): 331-339.
|